Match Document Document Title
6706271 Cloning of BASB023 antigen from Moraxella catarrhalis  
The invention provides BASB023 polypeptides encoding BASB023 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and...
6706494 BASB028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis  
The invention provides BASB028 polypeptides and polynucleotides encoding BASB028 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic,...
6706269 Moraxella catarrhalis PILQ proteins  
The invention provides BASB031 polypeptides and polynucleotides encoding BASB031 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic,...
6703360 Compositions and methods related to canine IgG and canine IL-13 receptors  
The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present...
6689365 Single-chain fertility hormones with fsh and LH activity  
Glycosylated or nonglycosylated proteins of the formula FSHβ-(linker 1 ) n 1 -LHβ(1-X)-(linker 2 ) n 2 -α wherein FSHβ is a vertebrate follicle stimulating hormone β subunit or a variant...
6689368 Immunodominant human T-cell epitopes of hepatitis C virus  
The present invention relates to a polypeptide of about 8 to about 100 amino acids comprising or consisting of at least 8 contiguous amino acids selected from the core, and/or the NS3 regions of...
6685941 Methods of treating autoimmune disease via CTLA-4Ig  
The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of...
6682739 Methods of inhibiting osteoclastogenesis  
Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. The present invention...
6682741 β2 microglobulin fusion proteins and high affinity variants  
β 2 -microglobulin fusion proteins and modified forms of β 2 -microglobulin are disclosed. The fusion proteins are shown to incorporate onto the surface of MHC I expressing mammalian cells and to...
6680058 Compositions and methods for contraception in or sterilization of mammals  
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and...
6680057 Methods of treating autoimmune disease by administering interleukin-17 receptor  
Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
6676945 Mycobacterial proteins, microorganisms producing them and their use for vaccines and for the detection of tuberculosis  
Mycobacterium tuberculosis protein having a molecular weight of 28.779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines...
6673574 Oral delivery of peptides using enzyme-cleavable membrane translocators  
Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine in addition to having the...
6673572 Methods for rescue of RNA viruses  
This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to...
6669939 (Poly)peptides which represent the epitopes of the human herpes virus type 8  
The present invention relates to (poly)peptides, which are recognized by anti-HHV8 antibodies of HHV-8 infected patients, whereby these (poly)peptides are not naturally occurring HHV-8 proteins....
6669941 Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease  
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents...
6663867 Hybrid heterodimeric protein hormone comprising a TNF binding protein and a glycoprotein hormone subunit and method of using same  
A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-β and...
6660274 Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease  
A novel isolated Borrielia burgdorferi sensu lato surface antigen is characterized by a relative molecular mass of 39.5 kDa. This antigen is expressed in vitro by spirochetes of a B. burgdorferi...
6660271 Ubiquitin fusion-based vaccine system  
Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising...
6653444 Polypeptides comprising a B7 extracellular domain  
Isolated nucleic acid molecules encoding a B cell activation antigen, B7, are provided. In one embodiment, the nucleic acid molecules are DNA sequences. The DNA sequences of the invention can be...
6652858 Use of OX-2 to suppress an immune response  
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an OX-2 protein or a nucleic acid encoding an OX-2 protein. The...
6653086 Endogenous constitutively activated G protein-coupled orphan receptors  
Disclosed herein are techniques for directly identifying candidate compounds as agonists, partial agonists and/or, most preferably, inverse agonists, to endogenous, constitutively activated orphan...
6652863 Method of reducing the immunogenicity of compounds  
Reduced-immunogenic fusion compounds are disclosed. The fusion compounds of the invention comprise immunogenic compounds linked to auto-antigenic sequences which render the compound less...
6649374 Recombinant Chlamydia trachomatis PGP3 antigen  
A new recombinant form of the plasmid-encoded protein pgp3 from C. trachomatis , serotype D, to be used in immunogenic compositions and in the preparation of immunogenic compositions was purified...
6649166 Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same  
The invention concerns peptides and proteins for desensitizing specifically the vast majority of subjects allergic to bee venom and compositions containing said peptides or proteins. The peptides...
6649164 Method for enhancing the functional capacity of dendritic cells  
Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to enhance the functional capacity of dendritic cells.
6649171 Moraxella catarrahalis polynucleotides and polypeptides  
The invention provides BASB021 polypeptides and polynucleotides encoding BASB021 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic,...
6645500 Method for down-regulating osteoprotegerin ligand activity  
The invention provides a novel method for down-regulating the biological activity of osteoprotegerin ligand (OPGL, TRANCE) thereby rendering possible the treatment/amelioration of diseases...
6645501 Anti-pathogen system and methods of use thereof  
The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically...
6641809 Method of regulating cellular processes mediated by B7 and CD28  
The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins...
6638511 Mycobacterium polypeptides and nucleic acids encoding them for diagnosis and control of tuberculosis  
The invention relates to nucleic acids which contain particularly a nucleotide sequence extending from the extremity constituted by the nucleotide at position (1) to the extremity constituted by...
6638518 Method for inhibiting inflammatory responses  
The present invention provides methods for treating at least one symptom of an inflammatory response in a mammal by administering a polypeptide to the mammal. The polypeptide can be a microbial...
6635472 Retrovirus and viral vectors  
This invention relates to the fields of genetic engineering, virus replication and gene transfer. More specifically, this invention relates to polynucleotide construct, recombinant virus,...
6635256 Glycoprotein hormone compositions comprising two β subunits and methods of use thereof  
Forms of differentially acting glycoprotein hormones are disclosed. These compositions are of the formula β 1 -(linker 1 ) m -α-(linker 2 ) n -β 2 (1); β 1 -(linker 1 ) m -β 2 -(linker 2 )...
6632436 Vaccine compositions and method of modulating immune responses  
The invention provides compositions and methods for modulating immune responses in subjects. The invention is based, at least in part, on the discovery that an in-frame translation fusion of an...
6630348 Single-chain insulin analog and a polynucleotide sequence encoding the analog  
The subject matter of the invention is directed to a single-chain insulin analog that is used to treat diabetes by gene therapy methods.
6613331 Vaccine against Lyme disease  
The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of ...
6613327 Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal  
Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated...
6610306 OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof  
Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis , and fragments thereof are useful in vaccine compositions, therapeutic compositions and...
6610473 Peptides for inhibiting HPV E6-proteins  
The present invention relates to peptides suited for inhibiting HPV-E6 proteins, DNAs encoding them and the use of both, particularly for eliminating HPV tumor cells.
6607724 Compositions and methods for inhibiting angiogenesis  
The invention provides for methods of reducing or inhibiting angiogenesis, tumor growth and endothelial cell proliferation by the administration of compositions containing fragments, conformations,...
6605699 Galectin-11 polypeptides  
The present invention relates to galectin 11 proteins which are members of the galectin superfamily. In particular, the present invention relates to full-length polypeptides, fragments, and...
6605286 Delivery of biologically active polypeptides  
Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The...
6602510 HLA class I A2 tumor associated antigen peptides and vaccine compositions  
A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4),...
6602504 Canine coronavirus S gene and uses therefor  
The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for...
6600018 Secreted frizzled related protein, sFRP, fragments and methods of use thereof  
The invention stems from the discovery that sFRP and fragments thereof can bind to members of the Wnt family of proteins and cause an increase in Wnt biological activity. Furthermore, fragments of...
6596278 Immunological response potentiation process  
An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles,...
6592872 Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein  
The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine...
6592871 HCV peptide antigens and methods for the determination of HCV  
Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as...
6586392 Conjugates of antiviral proteins or peptides and virus or viral envelope glycoproteins  
The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention...